Replies to post #520109 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

foxhound02, let me get this straight. So you are saying the following:

(1) The DCVax-L Phase III trial was positive, and it did meet both its Primary and Secondary endpoints with statistical significance; and

(2) DCVax-L did prove that it is efficacious, and it did significantly extend Overall Survival (OS) for both newly diagnosed GBM (ndGBM) and recurrent GBM (rGBM) patients; and

(3) DCVax-L also proved that it was very safe, and it did not cause any, or very few, serious adverse events (SAEs);

"BUT, DCVax-L will not be approved by regulatory authorities, even though it is safe and it help ndGBM and rGBM patients live longer".

Is that really what you are saying?